What do you do when someone believes you shouldn’t exist?

Daryl Davis didn’t protest. He didn’t shout. He sat down, asked questions, and kept showing up. Over decades, that approach has led more than 200 Ku Klux Klan members and white supremacists to walk away from their robes for good.

In this conversation, Davis explains why people radicalize, and what happens psychologically when prejudice collides with a real human being. He shares stories from inside Klan meetings, lessons learned from neo-Nazis, and why today’s climate of polarization may actually be an opportunity rather than a dead end.

Daryl Davis earned his Bachelor of Music degree from Howard University and an Honorary Doctorate in Humane Letters from Post University. He is the author of Klan-Destine Relationships and the subject of the multi-award-winning documentary Accidental Courtesy, which chronicles his work in race reconciliation. A lifelong musician, he has performed with Chuck Berry and President Bill Clinton, and as an actor appeared in HBO’s The Wire.

Open inquiry depends on the ability to ask uncomfortable questions and follow evidence wherever it leads. Eric Kaufmann argues that this norm is now under strain.

Drawing on history, survey data, and political theory, Kaufmann outlines how certain identity categories came to be treated as morally sacred—and how that shift has reshaped debates about equality, free speech, and academic inquiry. The conversation examines the long roots of today’s culture conflicts, the move from equal opportunity to equal outcomes, and why disagreement is increasingly interpreted as moral transgression rather than intellectual difference.

At stake is what happens to liberal societies when some questions can no longer be asked, nd whether open inquiry can still be defended without abandoning concern for fairness and dignity

Eric Kaufmann is a professor of politics and Director of the Centre for Heterodox Social Science at the University of Buckingham. He has written for The New York Times, Wall Street Journal, Times of London, Newsweek, National Review, New Statesman, Financial Times, and other outlets. His new book is The Third Awokening.

Brain-computer interfaces are moving out of the lab and into real medical use.

In this episode of The Michael Shermer Show, Michael Shermer talks with Dr. Matt Angle, founder and CEO of Paradromics, a neurotechnology company developing one of the most advanced high-data-rate brain implants in the world, similar to Neuralink. These devices record activity from individual neurons, making it possible to restore speech in people with paralysis, reconnect the brain to external devices, and potentially treat chronic pain and neurological disorders with far greater precision than existing approaches.

Angle explains why progress in neuroscience has been limited not by biology, but by data—how much information we can actually read from the brain, and how fast. He describes how patients who can no longer speak may soon communicate fluently using only brain signals, why invasive implants can sometimes be safer than long-term drug treatments, and what it takes to bring a brain implant through FDA approval and into the clinic.

The conversation also touches on the larger questions raised by this technology, including autonomy, consciousness, and what happens when the boundary between brain and machine begins to blur.

Matt Angle is the Founder and CEO of Paradromics, a neurotechnology leader developing the world’s most advanced and clinically viable brain-computer interface (BCI) platform—bridging human thought and digital capability. Paradromics’ BCI platform records brain activity with unmatched precision, capturing data at the level of individual neurons. This advanced technology enables the decoding of vast amounts of brain data, opening the door to next-generation treatments for paralysis, chronic pain, addiction, mental health conditions, and more. With the power of AI, this platform has the potential to radically shift how healthcare providers approach some of the most challenging medical conditions.

Angle earned his PhD in Neuroscience from the University of Heidelberg, followed by postdoctoral research at Stanford University. Paradromics engineered its first clinical product, the Connexus® BCI, received two FDA Breakthrough Device Designations, and performed the first-in-human neural recording in May 2025. The company is now preparing to launch a clinical trial in early 2026, pending regulatory approval.